Kelly Lawrence W & Associates’s AbbVie ABBV Stock Holding History

Kelly Lawrence W & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.96M	Sell	7,791 -150	-2%	-$32.3K	0.42%	33
2026 Q1	$1.73M	Sell	7,941 -1,016	-11%	-$225K	0.48%	32
2025 Q4	$2.05M	Sell	8,957 -20	-0.2%	-$4.56K	0.5%	33
2025 Q3	$2.08M	Sell	8,977 -560	-6%	-$114K	0.5%	33
2025 Q2	$1.77M	Hold	9,537	–	–	0.46%	32
2025 Q1	$2M	Sell	9,537 -300	-3%	-$58.3K	0.49%	34
2024 Q4	$1.75M	Buy	9,837 +86	+0.9%	+$15.8K	0.41%	37
2024 Q3	$1.93M	Sell	9,751 -235	-2%	-$43.9K	0.43%	35
2024 Q2	$1.71M	Sell	9,986 -850	-8%	-$141K	0.39%	39
2024 Q1	$1.97M	Sell	10,836 -115	-1%	-$19.8K	0.45%	37
2023 Q4	$1.7M	Hold	10,951	–	–	0.41%	38
2023 Q3	$1.63M	Sell	10,951 -100	-0.9%	-$14.7K	0.44%	38
2023 Q2	$1.52M	Sell	11,051 -2,167	-16%	-$318K	0.39%	39
2023 Q1	$2.11M	Hold	13,218	–	–	0.57%	35
2022 Q4	$2.14M	Hold	13,218	–	–	0.61%	35
2022 Q3	$1.77M	Sell	13,218 -250	-2%	-$35.9K	0.5%	35
2022 Q2	$2.06M	Hold	13,468	–	–	0.57%	37
2022 Q1	$2.18M	Sell	13,468 -335	-2%	-$48.7K	0.47%	37
2021 Q4	$1.87M	Sell	13,803 -742	-5%	-$87.6K	0.37%	38
2021 Q3	$1.57M	Hold	14,545	–	–	0.33%	40
2021 Q2	$1.64M	Buy	14,545 +200	+1%	+$22.5K	0.35%	40
2021 Q1	$1.55M	Buy	14,345 +9,860	+220%	+$1.05M	0.37%	40
2020 Q4	$481K	Sell	4,485 -11,660	-72%	-$1.12M	0.19%	43
2020 Q3	$1.41M	Hold	16,145	–	–	0.42%	32
2020 Q2	$1.58M	Hold	16,145	–	–	0.33%	34
2020 Q1	$1.23M	Hold	16,145	–	–	0.3%	38
2019 Q4	$1.43M	Hold	16,145	–	–	0.22%	43
2019 Q3	$1.22M	Hold	16,145	–	–	0.2%	44
2019 Q2	$1.18M	Hold	16,145	–	–	0.2%	46
2019 Q1	$1.3M	Hold	16,145	–	–	0.23%	45
2018 Q4	$1.49M	Sell	16,145 -8,900	-36%	-$783K	0.32%	42
2018 Q3	$2.37M	Hold	25,045	–	–	0.39%	41
2018 Q2	$2.32M	Sell	25,045 -100	-0.4%	-$9.77K	0.43%	40
2018 Q1	$2.38M	Sell	25,145 -1,200	-5%	-$132K	0.45%	40
2017 Q4	$2.55M	Sell	26,345 -250	-0.9%	-$23.6K	0.47%	42
2017 Q3	$2.36M	Sell	26,595 -100	-0.4%	-$7.61K	0.45%	42
2017 Q2	$1.94M	Hold	26,695	–	–	0.38%	46
2017 Q1	$1.74M	Sell	26,695 -350	-1%	-$22K	0.36%	45
2016 Q4	$1.69M	Buy	27,045 +200	+0.7%	+$12.2K	0.38%	44
2016 Q3	$1.69M	Sell	26,845 -350	-1%	-$22.7K	0.36%	45
2016 Q2	$1.68M	Buy	27,195 +12,035	+79%	+$733K	0.39%	45
2016 Q1	$866K	Buy	15,160 +4,350	+40%	+$242K	0.22%	47
2015 Q4	$640K	Buy	10,810 +1,300	+14%	+$74.9K	0.14%	51
2015 Q3	$517K	Sell	9,510 -400	-4%	-$26K	0.12%	59
2015 Q2	$666K	Hold	9,910	–	–	0.13%	55
2015 Q1	$580K	Hold	9,910	–	–	0.13%	55
2014 Q4	$648K	Sell	9,910 -150	-1%	-$9.46K	0.14%	56
2014 Q3	$581K	Hold	10,060	–	–	0.12%	57
2014 Q2	$567K	Sell	10,060 -250	-2%	-$13.1K	0.12%	58
2014 Q1	$530K	Sell	10,310 -560	-5%	-$28.3K	0.12%	58
2013 Q4	$574K	Sell	10,870 -440	-4%	-$21.6K	0.13%	58
2013 Q3	$506K	Hold	11,310	–	–	0.12%	61
2013 Q2	$467K	Buy	+11,310	New	+$495K	0.12%	62

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Kelly Lawrence W & Associates's ABBV Position: Q2 2026 in Review

Kelly Lawrence W & Associates reduced its AbbVie (ABBV) stake by 1.9% in Q2 2026, selling an estimated $32.3K and leaving 7,791 shares worth $1.96M. The position accounts for 0.42% of the portfolio, ranked #33.

Kelly Lawrence W & Associates first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.55M in Q4 2017. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Kelly Lawrence W & Associates held 7,791 shares of AbbVie worth $1.96M as of Q2 2026.
Kelly Lawrence W & Associates sold 150 AbbVie shares in Q2 2026, an estimated $32.3K.
AbbVie made up 0.42% of Kelly Lawrence W & Associates's portfolio in Q2 2026, its #33 holding.
Kelly Lawrence W & Associates first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
Kelly Lawrence W & Associates's AbbVie position peaked at $2.55M in Q4 2017.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Kelly Lawrence W & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.